Rory McCulloch

Rory McCulloch

Auto-generated profile, based on publicly available information

Rory McCulloch

Department of Haematology Gloucestershire Hospitals NHS Foundation Trust Gloucester UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
SGSteven Le Gouill
Steven Le Gouill
FMFranck Morschhauser
Franck Morschhauser
DCDavid Chiron
David Chiron
KBKrimo Bouabdallah
Krimo Bouabdallah
GCGuillaume Cartron
Guillaume Cartron
SRSimon Rule
Simon Rule
Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was reported, and venetoclax at 400 mg per day was chosen for extension. Eighteen (75%) relapsed and 8 (53%) untreated patients experienced grade 3/4 adverse events. The complete response rate assessed by positron emission tomography at the end of cycle 6 was 67% in relapsed and 86.6% in untreated patients. MRD clearance for evaluable patients was seen in 71.5% of relapsed (10/14 patients) and 100% of untreated MRD-evaluable patients (n = 12) at the end of 3 cycles. The median follow-up for relapsed patients was 17 months (range, 10-35 months). The 2-year progression-free survival (PFS) was 69.5% (95% confidence interval [CI], 52.9%-91.4%) and 68.6% (95% CI, 49.5%-95.1%) for overall survival. The median follow-up was 14 months (range, 5-19) for untreated patients, the 1-year PFS was 93.3% (95% CI, 81.5%-100%). The combination of obinutuzumab, ibrutinib, and venetoclax is well tolerated and provides high response rates, including at the molecular level, in relapsed and untreated MCL patients. This trial was registered at www.clinicaltrials.gov as #NCT02558816.

3 February 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RMRory McCulloch
Rory McCulloch
CVCarlo Visco
Carlo Visco
TEToby A. Eyre
Toby A. Eyre
RFRebecca Frewin
Rebecca Frewin
NPNeil Phillips
Neil Phillips
SRSimon Rule
Simon Rule

23 February 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
RMRory McCulloch
Rory McCulloch
DLDavid Lewis
David Lewis
NCNicola Crosbie
Nicola Crosbie
TEToby Eyre
Toby Eyre
SBSimon Bolam
Simon Bolam
SRSimon Rule
Simon Rule
Summary: Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when given second line in a real‐world setting. Our multicentre retrospective analysis included 211 R/R MCL patients, median age 73 years, receiving ibrutinib second‐line within the United Kingdom’s National Health Service. Overall response to ibrutinib was 69% (complete response 27%). The median progression‐free survival (PFS) was 17·8 months (95% CI 13·1–22·2) and median overall survival (OS) 23·9 months (95% CI 15·0–32·8). Drug‐related adverse event led to dose reduction in 10% of patients and discontinuation in 5%. In patients with progressive disease, accounting for 100 of 152 patients stopping ibrutinib, 43% received further systemic therapy. Post‐ibrutinib rituximab, bendamustine and cytarabine (R‐BAC) showed a trend toward improved survival compared to alternative systemic treatments (post‐ibrutinib median OS 14·0 months, 95% CI 8·1–19·8, vs. 3·6 months, 95% CI 2·6–4·5, P = 0·06). Our study confirms the clinical benefit and good tolerability of ibrutinib at first relapse in a real‐world population. Patients progressing on ibrutinib had limited survival but outcomes with R‐BAC in select patients were promising.

31 March 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NMNicolás Martinez‐Calle
Nicolás Martinez‐Calle
EPEdward Poynton
Edward Poynton
AAAlia Alchawaf
Alia Alchawaf
SKShireen Kassam
Shireen Kassam
MHMatthew Horan
Matthew Horan
KCKate Cwynarski
Kate Cwynarski

25 October 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
TEToby Eyre
Toby Eyre
MBMark J. Bishton
Mark J. Bishton
RMRory McCulloch
Rory McCulloch
MOMaeve O'REilly
Maeve O'REilly
RSRobin Sanderson
Robin Sanderson
THThe Haemato‐Oncology Task Force Of The British Society For Haematology
The Haemato‐Oncology Task Force Of The British Society For Haematology

11 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
DVDiego Villa
Diego Villa
AJAixiang Jiang
Aixiang Jiang
CVCarlo Visco
Carlo Visco
NCNicola Crosbie
Nicola Crosbie
RMRory McCulloch
Rory McCulloch
DLDavid Lewis
David Lewis
Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range of 1L, second-line (2L), and subsequent lines of therapy. The purpose of this study was to evaluate the factors predicting outcomes in patients with relapsed/refractory (R/R) MCL exclusively initiating 2L Bruton’s tyrosine kinase inhibitors (BTKis) after 1L rituximab-containing therapy. Patients were accrued from 8 international centers (7 main, 1 validation cohort). Multivariable models evaluating the association between time to POD and clinical/pathologic factors were constructed and converted into nomograms and prognostic indexes predicting outcomes in this population. A total of 360 patients were included, including 160 in the main cohort and 200 in the validation cohort. Time to POD, Ki67 ≥ 30%, and MCL International Prognostic Index (MIPI) were associated with progression-free survival (PFS2) and overall survival (OS2) from the start of 2L BTKis. C-indexes were consistently ≥0.68 in both cohorts. Web/application-based calculators based on nomograms and prognostic indexes to estimate PFS2 and OS2 were constructed. The 2L BTKi MIPI identifies 3 groups with distinct 2-year PFS2, including high risk (14%), intermediate risk (50%), and low risk (64%). Time to POD, Ki67, and MIPI are associated with survival outcomes in patients with R/R MCL receiving 2L BTKis. Simple clinical models incorporating these variables may assist in planning for alternative therapies such as chimeric antigen receptor T-cell therapy, allogeneic stem cell transplantation, or novel agents with alternative mechanisms of action.